Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 16
Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer
Panelists discuss how to choose among therapeutic options when multiple molecular alterations are detected, identify patient populations better suited to specific therapies, and share their excitement about potential advances in the HR+/HER2– breast cancer space.
Video content above is prompted by the following:
- Dr. Bardia to All Panelists: How do you choose amongst the therapeutic options if multiple molecular alterations are detected?
- Are there particular patient populations that are better suited to one therapy or class over aanother?
- Dr. Bardia to All Panelists: What other potential advances are you excited about in the HR+/HER2–- breast cancerBC space?
Related Content:
